This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
MHRA.Direct Healthcare Professional Communication on strengthening the cardiovascular monitoring during treatment initiation with Gilenya (fingolimod) in patients with Relapsing Remitting Multiple Sclerosis. Internet Document: [2 pages], 23 Jan 2012. Available from: URL: http://www.mhra.gov.uk
About this article
Cite this article
Monitoring CV status in fingolimod patients crucial, says Novartis. React. Wkly. 1388, 2 (2012). https://doi.org/10.2165/00128415-201213880-00002
- Public Health
- Clinical Trial
- Multiple Sclerosis
- Healthcare Professional